Author:
Dai Tianming,Jiang Weifan,Wang Min,Guo Zizheng,Dai Renke
Reference23 articles.
1. AstraZeneca Pharmaceuticals LP, 2015. Iressa Label (6/17/2005). https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008lbl.pdf.
2. The relative bioavailability of gefitinib administered by granular formulation;Cantarini;Cancer. Chemother. Pharmacol.,2008
3. Pharmacokinetic and pharmacodynamic study of gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis;Chen;Lung Cancer,2013
4. Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187;Domotor;J. Pharm. Biomed. Anal.,2018
5. European Medicines Evaluation Agency, 2001. Note for guidance on the investigation of bioavailability and bioequivalence, https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-investigation-bioavailability-bioequivalence_en.pdf.